Johnson Johnson (NYSE: JNJ) is one of the top healthcare companies in the world. Last year, it spun off its consumer health business to focus on growing other parts of its operations, which include innovative medicines and medical devices. And over the years, the company expects growth of 5-7%.

But Johnson Johnson still faces uncertainty around its talc lawsuits, which may put a strain on its cash flow. It's also facing a loss in exclusivity in one of its top-selling drugs, Stelara, in the near future. The company is facing multiple headwinds that could affect its ability to generate significant growth, despite its optimism.

Rather than investing in Johnson Johnson, which is a bit of a risky investment given its ongoing legal battles, healthcare investors who are looking for growth have a more promising opportunity in Abbott Laboratories (NYSE: ABT).

Continue reading

Source Fool.com